Entolimod
id:
entolimod-250-13503307
title:
Entolimod
text:
Entolimod (CBLB502) is being developed by Cleveland Biolabs, Inc. for dual indications under the U.S. Food & Drug Administration’s (FDA) animal efficacy rule as a pivotal-stage radiation countermeasure, and under the FDA’s traditional drug approval pathway as a cancer treatment. Entolimod is a recombinant protein that acts as an agonist of toll-like receptor 5 (TLR5), an innate immunity receptor. Entolimod activation of TLR5 triggers NF-κB signaling, mobilizing an innate immune response that dri
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Entolimod
date created:
date modified:
2023-11-08T11:51:14Z
main entity:
{"identifier":"Q5009129","url":"https://www.wikidata.org/entity/Q5009129"}
image:
fields total:
13
integrity:
14